In Vivo Pharmacodynamic Evaluation of Psoriasis Model (CAT#: STEM-AE-0674-LGZ)

Introduction

Autoimmune diseases are conditions in which your immune system mistakenly attacks your body. The immune system normally defends against bacteria such as bacteria and viruses. When it senses these foreign invaders, it sends a combat force against them. Usually, the immune system can tell the difference between foreign cells and your own. In autoimmune diseases, the immune system mistakes a part of the body, such as a joint or skin, for a foreign body. It releases proteins called autoantibodies that attack healthy cells. Some autoimmune diseases target only one organ. Type 1 diabetes damages the pancreas. Other diseases, such as systemic lupus erythematosus (SLE), can also affect the whole body.

Add to Cart Please Inquire

Principle Applications Procedure Materials Notes Related Products

Principle

Psoriasis is a skin disease characterized by epidermal keratinocyte hyperplasia that is mediated by cells and molecules of the innate and adaptive immune systems and is the result of a combination of genetic, epigenetic, and environmental influences. The most commonly used animal model in preclinical studies is the imiquimod (IMQ) -induced skin lesion and skin inflammation model, which has a phenotype similar to human psoriasis. IMQ can cause skin injury in mice, increase the degree of rash and desquamate, skin epidermis thickening, and dermis dominated by keratosis and inflammatory leukocyte infiltration can be seen histopathologically. IL-23/IL-17 has proinflammatory effects and is thought to be particularly important in the pathogenesis of psoriasis. IL-17 cytokine levels were significantly elevated in IMQ-induced psoriasis models.

Applications

Autoimmune Disease

Procedure

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

Materials

• Sample Type: liquid or powder

Other recommended products

In Vivo Pharmacodynamic Evaluation of B-hNKG2D Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0324-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hNKP46 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0313-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hCX3CR1 Mice (GPCR Humanized Mice) (CAT#: STEM-AE-0559-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hPD-L1/hLAG3 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0386-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hJAM3 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0200-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hPD-1/hPD-L1/hCD40 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0404-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hHER2 Mice (Humanized Mice) (CAT#: STEM-AE-0578-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hCD22 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0234-LGZ)